Study Type--Therapy (cohort) Level of Evidence 2a. What's known on the subject? and What does the study add? @entity1 -reported quality of life (QoL) in @entity263 is recognized as an important outcome, and has been shown in multiple studies to capture the incidence and timing of @entity1 symptoms more accurately than physician-graded @entity137 reports. Although the long-term QoL after completing @entity1161 ( @entity1161 ) has been previously studied, @entity1 experience during @entity1161 is not well described in the literature. The present study collected @entity1 -reported QoL during @entity1161 in a prospective phase II clinical trial. The study describes in detail the time course and severity of @entity344 during radiation, providing clinically useful information for @entity1 and physicians considering @entity1161 during the treatment decision-making process. OBJECTIVE:     To evaluate data collected from a phase II trial to describe the time course and trajectory of @entity1 -reported acute urinary and bowel symptom development during @entity1161 ( @entity1161 ) for @entity263 . @entity1 AND METHODS:     In all, 100 @entity1 with intermediate- or high-risk @entity263 received 72 Gy of @entity1161 to the prostate and seminal vesicles, with 6 months of concurrent @entity342 deprivation therapy; a rectal balloon was used for prostate immobilization.     @entity1 completed the validated Prostate Cancer Symptom Indices questionnaire every 1-2 weeks, reporting urinary and bowel symptoms on a four- or five-point Likert scale.     A score of >=  3 in a symptom is associated with clinically meaningful distress. Cumulative incidence of each symptom is reported. Bonferroni corrections of P values were used to adjust for multiple comparisons. RESULTS:     Urinary symptoms were frequent at baseline and worsened during treatment. By the end of @entity1161 , 28-50% of @entity1 developed clinically meaningful obstructive and irritative urinary symptoms.     @entity697 were less frequent. Each bowel symptom increased in frequency by 9-26% from baseline to end of @entity1161 .     @entity322 was rare.     Overall, symptom burden at the end of treatment was modest. CONCLUSIONS:     Urinary symptoms were common during @entity1161 , and bowel symptoms were less frequent.     These results inform @entity1 and physicians during the decision-making process about potential @entity1 quality of life experiences during @entity1161 , and also provide a benchmark for comparative effectiveness studies against newer treatments and technologies.

@entity1 -reported quality of life during radiation treatment for XXXX : results from a prospective phase II trial.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'PATIENTS', 'Patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer'] @entity697 :: ('MESH:D000208', 'Disease') :: ['Acute bowel symptoms'] @entity322 :: ('MESH:D014549', 'Disease') :: ['Urinary incontinence'] @entity1161 :: ('MESH:D011832', 'Disease') :: ['radiation therapy', 'RT'] @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal and genitourinary symptoms'] @entity342 :: ('CHEBI:50113', 'Chemical') :: ['androgen']
@entity263 :: (MESH:D011471,Disease) :: ['localized prostate cancer']
